- Abbott Laboratories ABT announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a minimally invasive device designed specifically for tricuspid heart valve repair.
- The TRILUMINATE Pivotal study evaluates the superiority of TriClip compared to medical therapy in treating patients with severe, symptomatic tricuspid regurgitation (TR) at intermediate or greater risk for open-heart surgery.
- Tricuspid regurgitation is a disorder where this valve does not close tight enough. This problem causes blood to flow backward into the right upper heart chamber.
- The trial met its composite primary endpoint demonstrating the superiority of the TriClip system compared to the control group (win ratio 1.48, p=0.02), primarily driven by improvement in quality of life.
- Also Read: Abbott Adds Complementary Technologies To Its Vascular Offering Via Cardiovascular Systems Deal For $890M.
- Mortality or tricuspid valve surgery and heart failure hospitalizations did not appear different between the groups at one year.
- Significant reduction in TR to moderate or less (grade < 2) was achieved in 87% of patients with the device at 30 days vs. 4.8% in the control group, with TR reduction sustained and durable at one year.
- At 30 days, only 1.7% of patients who received the device experienced major adverse events, with no urgent surgery or endocarditis.
- There were no occurrences of device embolization or device thrombus.
- Price Action: ABT shares closed at $104.45 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in